Tracon's IV TRC105 misses primary in Ph II GBM trial

In February, Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported top-line data from the Phase II portion of a Phase I/II trial to treat recurrent glioblastoma multiforme (GBM) showing that IV TRC105 (carotuximab) plus Avastin bevacizumab missed the primary endpoint of improving progression-free survival (PFS) vs. Avastin alone. The open-label, U.S. trial enrolled 101 patients with recurrent GBM who previously received chemoradiation to receive Avastin with or without TRC105. TRC105 plus Avastin also missed the secondary endpoint of improving overall survival (OS) vs. Avastin alone. Other secondary endpoints in the trial include safety and quality of life (QOL). Additional data from the trial, which was sponsored by the NCI, are expected this year. Tracon said it has no plans to continue development of the product in GBM...